Treatment of interleukin (IL)-12 mediated illnesses comprises simultaneous administration of thalidomide or analogue and antiinflammatory cytokine

摘要

Illnesses caused by the formation of interleukin (IL)-12 are treated and prevented by the simultaneous administration of a thalidomide alpha -methyl-thalidomide (EM 987) or 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (EM 12) antiinflammatory cytokine. The thalidomide compound is thalidomide,